author-photo

Alfredo Zurlo

21

Papers

249

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors

2020 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas

2018
Show All
- Source
- Cite
- Save
Citations (10)
Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
LBA41A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Immunomodulatory switch maintenance therapy in metastatic colorectal carcinoma: The phase III IMPALA study.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
2089 Response to chemotherapy allows to identify mCRC patients most likely to benefit from maintenance immunotherapy: A post-hoc analysis from the IMPACT study

2015 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B61: Exploratory analyses of the randomized phase 2 IMPACT study: Patients with response to prior induction chemotherapy have improved outcome when treated with the TLR-9 agonist MGN1703

2015 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (0)